Reactive oxygen species (ROS) such as superoxide (O2-) generated by NAD(P)H oxidases have emerged as important molecules in blood pressure regulation. This study investigated the effect of apocynin and catalase on blood pressure and renal haemodynamic and excretory function in an L-NAME induced hypertension model. Forty Male Wistar-Kyoto (WKY) rats (n=8 per group) were treated with either: vehicle (WKY-C); L-NAME (WKY-L, 15 mg/kg/day in drinking fluid); WKY-L given apocynin to block NAD(P)H oxidase (WKY-LApo, 73 mg/kg/day in drinking water.); WKY-L given catalase to enhance ROS scavenging (WKY-LCat, 10000 U/kg/day i.p.); and WKY-L receiving apocynin plus catalase (WKY-LApoCat) daily for 14 days. L-NAME elevated systolic blood pressure (SBP), 116+/-1 to 181±4 mmHg, reduced creatinine clearance, 1.69+/-0.26 to 0.97+/-0.05 ml/min/kg and fractional sodium excretion, 0.84+/-0.09 to 0.55+/-0.09 % at day 14. Concomitantly, plasma malondialdehyde (MDA) increased six fold, while plasma total superoxide dismutase (T-SOD), plasma nitric oxide (NO) and plasma total antioxidant capacity (T-AOC) were decreased by 60-70 % and Nox 4 mRNA expression was increased 2-fold. Treatment with apocynin and catalase attenuated the increase in SBP and improved renal function, enhanced antioxidative stress capacity and reduced the magnitude of Nox4 mRNAs expression in the L-NAME treated rats. This study demonstrated that apocynin and catalase offset the development of L-NAME induced hypertension, renal dysfunction and reduced oxidative stress status, possibly contributed by a reduction in Nox4 expression during NOS inhibition. These findings would suggest that antioxidant compounds such as apocynin and catalase have potential in treating cardiovascular diseases.

Cardiovascular and Renal Physiology Research Laboratory School of Pharmaceutical Sciences Universiti Sains Malaysia Minden Penang Malaysia

Center of Drug Research Universiti Sains Malaysia Minden Penang Malaysia

Department of Endocrinology School of Medicine University of Virginia Charlottesville Virginia USA

Department of Pharmaceutical Technology School of Pharmaceutical Sciences Universiti Sains Malaysia Minden Penang Malaysi

Department of Pharmacology School of Pharmaceutical Sciences Universiti Sains Malaysia Minden Penang Malaysia

Department of Pharmacy Abasyn University Islamabad Campus Islamabad Pakistan

Department of Pharmacy Islamia University of Bahawalpur Bahawalpur Pakistan

Department of Physiology School of Medicine University College of Cork Cork Ireland

Institute for Research in Molecular Medicine Universiti Sains Malaysia Minden Penang Malaysia

Literatura

000      

00000naa a2200000 a 4500

001      

bmc22000817

003      

CZ-PrNML

005      

20220202102828.0

007      

ta

008      

220106s2021 xr d f 000 0|eng||

009      

AR

024    7_

$a 10.33549/physiolres.934497 $2 doi

035    __

$a (PubMed)33728924

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xr

100    1_

$a Chia, T. Y. $u Cardiovascular and Renal Physiology Research Laboratory, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang, Malaysia

245    10

$a Inhibition of L-NAME-induced hypertension by combined treatment with apocynin and catalase: the role of Nox 4 expression / $c T. Y. Chia, V. Murugaiyah, N. A. Khan, M. A. Sattar, M. H. Abdulla, E. J. Johns, A. Ahmad, Z. Hassan, G. Kaur, H. Y. Mei, F. U. Ahmad, S. Akhtar

504    __

$a Literatura

520    9_

$a Reactive oxygen species (ROS) such as superoxide (O2-) generated by NAD(P)H oxidases have emerged as important molecules in blood pressure regulation. This study investigated the effect of apocynin and catalase on blood pressure and renal haemodynamic and excretory function in an L-NAME induced hypertension model. Forty Male Wistar-Kyoto (WKY) rats (n=8 per group) were treated with either: vehicle (WKY-C); L-NAME (WKY-L, 15 mg/kg/day in drinking fluid); WKY-L given apocynin to block NAD(P)H oxidase (WKY-LApo, 73 mg/kg/day in drinking water.); WKY-L given catalase to enhance ROS scavenging (WKY-LCat, 10000 U/kg/day i.p.); and WKY-L receiving apocynin plus catalase (WKY-LApoCat) daily for 14 days. L-NAME elevated systolic blood pressure (SBP), 116+/-1 to 181±4 mmHg, reduced creatinine clearance, 1.69+/-0.26 to 0.97+/-0.05 ml/min/kg and fractional sodium excretion, 0.84+/-0.09 to 0.55+/-0.09 % at day 14. Concomitantly, plasma malondialdehyde (MDA) increased six fold, while plasma total superoxide dismutase (T-SOD), plasma nitric oxide (NO) and plasma total antioxidant capacity (T-AOC) were decreased by 60-70 % and Nox 4 mRNA expression was increased 2-fold. Treatment with apocynin and catalase attenuated the increase in SBP and improved renal function, enhanced antioxidative stress capacity and reduced the magnitude of Nox4 mRNAs expression in the L-NAME treated rats. This study demonstrated that apocynin and catalase offset the development of L-NAME induced hypertension, renal dysfunction and reduced oxidative stress status, possibly contributed by a reduction in Nox4 expression during NOS inhibition. These findings would suggest that antioxidant compounds such as apocynin and catalase have potential in treating cardiovascular diseases.

650    _2

$a acetofenony $x farmakologie $7 D000098

650    _2

$a zvířata $7 D000818

650    _2

$a antioxidancia $x farmakologie $7 D000975

650    _2

$a katalasa $x farmakologie $7 D002374

650    _2

$a modely nemocí na zvířatech $7 D004195

650    _2

$a kombinovaná farmakoterapie $7 D004359

650    _2

$a inhibitory enzymů $x toxicita $7 D004791

650    _2

$a hemodynamika $7 D006439

650    _2

$a hypertenze $x chemicky indukované $x farmakoterapie $x patofyziologie $7 D006973

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a NADPH-oxidasa 4 $x metabolismus $7 D000074663

650    _2

$a NG-nitroargininmethylester $x toxicita $7 D019331

650    _2

$a krysa rodu Rattus $7 D051381

650    _2

$a potkani inbrední WKY $7 D011921

650    _2

$a reaktivní formy kyslíku $x metabolismus $7 D017382

655    _2

$a časopisecké články $7 D016428

700    1_

$a Murugaiyah, V. $u Department of Pharmacology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang, Malaysia

700    1_

$a Khan, N. A. K. $u Department of Pharmaceutical Technology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang, Malaysi

700    1_

$a Sattar, M. A. $u Cardiovascular and Renal Physiology Research Laboratory, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang, Malaysia

700    1_

$a Abdulla, M. H. $u Department of Physiology, School of Medicine, University College of Cork, Cork, Ireland

700    1_

$a Johns, E. J. $u Department of Physiology, School of Medicine, University College of Cork, Cork, Ireland

700    1_

$a Ahmad, A. $u Department of Pharmacy, Abasyn University Islamabad Campus, Islamabad, Pakistan

700    1_

$a Hassan, Z. $u Center of Drug Research, Universiti Sains Malaysia, Minden, Penang, Malaysia

700    1_

$a Kaur, G. $u Institute for Research in Molecular Medicine, Universiti Sains Malaysia, Minden, Penang, Malaysia

700    1_

$a Mei, H. Y. $u Department of Pharmaceutical Technology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang, Malaysi

700    1_

$a Ahmad, F. U. $u Department of Pharmacy, Islamia University of Bahawalpur, Bahawalpur, Pakistan

700    1_

$a Akhtar, S. $u Department of Endocrinology, School of Medicine, University of Virginia, Charlottesville, Virginia, USA

773    0_

$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 70, č. 1 (2021), s. 13-26

856    41

$u https://pubmed.ncbi.nlm.nih.gov/33728924 $y Pubmed

910    __

$a ABA008 $b A 4120 $c 266 $y p $z 0

990    __

$a 20220106 $b ABA008

991    __

$a 20220202102816 $b ABA008

999    __

$a ok $b bmc $g 1755648 $s 1151963

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2021 $b 70 $c 1 $d 13-26 $e 20210317 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824

LZP    __

$b NLK118 $a Pubmed-20220106